A team of inventive scientists, tech entrepreneurs and pioneering practitioners working in tandem to catalyze successful health innovation.
SGI At A Glance
SPRIM Global Investments is a privately held investment company. SGI was established in 2008 following the global expansion of SPRIM Consulting & Services business.
SPRIM Global Investments leverages the funnel of SPRIM’s sourcing, screening and selection processes across the globe to identify and invest in high potential health solutions. We find dynamic young companies proposing innovative offerings and help them to accelerate their growth. These startups can, in turn, leverage the SPRIM network, enabling them to fast-track their development. Our portfolio companies have full access to SPRIM’s fellow venture company experts across the globe as well as the company’s investment vehicles.
Areas Of Focus
SPRIM Global Investments invests principally in companies that provide R&D capabilities to bring life science, biotech and medtech innovations to patients around the world. Our portfolio of R&D Service/CRO and digital technology companies are addressing many of the pain points across the different clinical stages of drug and device development. Additionally, SGI leverages its unique vantage point in clinical stages to invest in Biotech and in Medtech.
We Build Companies For The Future Of Health.
SPRIM believes in maximizing the potential of innovative digital health and life science innovations by providing scientific, clinical and entrepreneurial expertise to foster bold, new, innovative solutions to the world’s biggest health problems.
Our portfolio companies leverage the capabilities and network of SGI investments in R&D Services, Healthcare IT and digital solutions across 17 offices, strategically placed throughout Asia-Pacific, Europe and the Americas.
545 West 25th Street,
20th Floor New York,
NY, USA 10001
79 Science Park Drive
Level 06 Unit 01/08
CINTECH IV, Science Park 1
We invest to bring better solutions for companies to develop and commercialize their innovations in life science.
R&D Services/CRO and Digital Health/HCIT
From early stage to growth stage, we look for innovative services and software solutions to improve the conduct and outcomes of clinical trials, regulatory processes and commercialization of drugs and medical technologies.
We invest in preclinical as well as clinical stage companies, primarily in neurology, oncology and fibrosis.
We invest in medtech and digital therapeutics after tne PoC stage.